CABA

Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). Resecabtagene autoleucel, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.

Wall Street analysts forecast CABA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CABA is 17.83 USD with a low forecast of 10.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Cabaletta Bio Inc revenue for the last quarter amounts to -46.59M USD, increased 40.98 % YoY.

Cabaletta Bio Inc. EPS for the last quarter amounts to -34587000.00 USD, increased 68.09 % YoY.

Cabaletta Bio Inc (CABA) has 161 emplpoyees as of December 15 2025.

Today CABA has the market capitalization of 227.19M USD.